ONCYONCOLYTICS BIOTECH INC

• 2026-03-13 · Kelly Jared (Chief Executive Officer) · BUY
• 2026-03-13 · Parsons James T. (Director) · BUY
• 2026-02-13 · Kelly Jared (Chief Executive Officer) · BUY
• 2026-02-13 · Hagerman Allison (VP, Product Development) · BUY
• 2026-02-13 · Look Kirk (Chief Financial Officer) · BUY

• Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
• Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
• NeOnc, BriaCell, and Oncolytics report cancer clinical and regulatory developments
• ONCOLYTICS BIOTECH INC · 8-K (8.01)
• Oncolytics Biotech reports positive preclinical results for pelareorep combination